Skip to main content
  • Saved

made a Post

Efficacy and Safety of Lower-Sodium Oxybate in a Phase 3, Placebo-Controlled, Double-Blind, Randomized Withdrawal Study in Adult Participants With Idiopathic Hypersomnia (2659)

Source :

https://n.neurology.org/content/96/15_Supplement/2659.abstract

Objective: Evaluate efficacy/safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB], Xywav™; previously designated JZP-258), a novel oxybate treatment with 92% less sodium than sodium oxybate (SXB; Xyrem®) in adults with idiopathic hypersomnia (IH). Background: IH is a rare central hypersomnolence disorder characterized by severe daytime sleepiness, prolonged nighttime sleep, and sleep inertia.